{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:42:29Z","timestamp":1789645349815,"version":"4.0.0"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T00:00:00Z","timestamp":1398124800000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:p>Epidemiological projections of the prevalence of Alzheimer's disease (AD) and related dementias, the rapidly expanding population over the age of 65, and the enormous societal consequence on health, economics, and community foretell of a looming global public health crisis. Currently available treatments for AD are symptomatic, with modest effect sizes and limited impact on longer term disease outcomes. There have been no newly approved pharmaceutical treatments in the last decade, despite enormous efforts to develop disease\u2010modifying treatments directed at Alzheimer's\u2010associated pathology. An unprecedented collaborative effort of government, regulators, industry, academia, and the community at\u2010large is needed to address this crisis and to develop an actionable plan for rapid progress toward successfully developing effective treatments. Here, we map out a course of action in four key priority areas, including (1) addressing the fundamental mechanisms of disease, with the goal of developing a core set of research tools, a framework for data sharing, and creation of accessible validated and replicated disease models; (2) developing translational research that emphasizes rapid progress in disease model development and better translation from preclinical to clinical stages, deploying leading technologies to more accurately develop predictive models; (3) preventing AD through the development of robust methods and resources to advance trials and creating fundamental resources such as continuous adaptive trials, registries, data repositories, and instrument development; and (4) innovating public\/private partnerships and global collaborations, with mechanisms to incentivize collaborations and investments, develop larger precompetitive spaces, and more rapid data sharing.<\/jats:p>","DOI":"10.1111\/nyas.12424","type":"journal-article","created":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T11:40:48Z","timestamp":1398166848000},"page":"1-16","source":"Crossref","is-referenced-by-count":27,"title":["Alzheimer's disease research and development: a call for a new research roadmap"],"prefix":"10.1111","volume":"1313","author":[{"given":"Howard H.","family":"Feldman","sequence":"first","affiliation":[{"name":"Division of Neurology, Faculty of Medicine University of British Columbia  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Haas","sequence":"additional","affiliation":[{"name":"One Mind for Research  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Gandy","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine and James J. Peters VA Medical Center  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryle D.","family":"Schoepp","sequence":"additional","affiliation":[{"name":"Merck and Company Inc, North Wales  Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Cross","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals LP  Wilmington Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mayeux","sequence":"additional","affiliation":[{"name":"Department of Neurology Sergievsky Center Columbia University  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa A.","family":"Sperling","sequence":"additional","affiliation":[{"name":"Department of Neurology Center for Alzheimer Research and Treatment, Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Fillit","sequence":"additional","affiliation":[{"name":"Alzheimer's Drug Discovery Foundation  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana L.","family":"van de Hoef","sequence":"additional","affiliation":[{"name":"The New York Academy of Sciences  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Dougal","sequence":"additional","affiliation":[{"name":"Steven and Alexandra Cohen Veterans Center at New York University Langone Medical Center  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Nye","sequence":"additional","affiliation":[{"name":"Janssen R&amp;D LLC, Johnson and Johnson Innovation  Titusville New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of One Mind for Research and the New York Academy of Sciences","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000109998"},{"key":"e_1_2_10_3_1","volume-title":"International statistical classification of diseases and related health problems","year":"2010"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21706"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurger.2010.07.012"},{"key":"e_1_2_10_6_1","volume-title":"Dementia: a public health priority","year":"2012"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610206003462"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.129.6.946"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.23.2215"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-5-200803040-00009"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3505"},{"key":"e_1_2_10_12_1","unstructured":"Sperling R. S.Salloway M.Raskind et al.2012.A randomized double\u2010blind placebo\u2010controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E \u03b54 carriers. Presented at: 16th European Federation of Neurological Societies Congress; September 11 Stockholm Sweden."},{"key":"e_1_2_10_13_1","unstructured":"Eli Lilly and Company.2012.Lilly announces detailed results of the Phase 3 solanezumab EXPEDITION studies following a presentation of the independent analyses by the Alzheimer's Disease Cooperative Study (ADCS).https:\/\/investor.lilly.com\/releasedetail.cfm?ReleaseID=711933. October 8 2012."},{"key":"e_1_2_10_14_1","unstructured":"Eli Lilly and Company.2012.Lilly provides update on next steps for solanezumab [press release].https:\/\/investor.lilly.com\/releasedetail.cfm?ReleaseID=726309. December 12 2012."},{"key":"e_1_2_10_15_1","unstructured":"http:\/\/www.alzforum.org\/news\/conference\u2010coverage\/solanezumab\u2010selected\u2010alzheimers\u2010a4\u2010prevention\u2010trial. January 2013;http:\/\/www.alzforum.org\/news\/research\u2010news\/dian\u2010trial\u2010picks\u2010gantenerumab\u2010solanezumab\u2010maybe\u2010bace\u2010inhibitor. October 2012."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70299-6"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753"},{"key":"e_1_2_10_18_1","unstructured":"http:\/\/www.alzforum.org\/news\/research\u2010news\/solanezumab\u2010benefit\u2010oh\u2010so\u2010small\u2010probably\u2010real?id=3288. October 2012."},{"issue":"9","key":"e_1_2_10_19_1","first-page":"774","article-title":"6th Conference Clinical Trials on Alzheimer's Disease ABSTRACTS","volume":"17","journal-title":"J. Nutr. Health Aging"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000435556.21319.e4"},{"key":"e_1_2_10_21_1","unstructured":"Some hope seen in Negative IVIG Alzheimer Trial.http:\/\/www.medpagetoday.com\/MeetingCoverage\/AAIC\/40493. July 16 2013."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c6784a"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1220-13.2013"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.06.016"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063162"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.1070"},{"key":"e_1_2_10_27_1","unstructured":"National Plan to Address Alzheimer's Disease:2013.Update.http:\/\/aspe.hhs.gov\/daltcp\/napa\/NatlPlan2013.pdf"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10821"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025788"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12417"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnyas.12424","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nyas.12424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/nyas.12424","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nyas.12424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T18:49:09Z","timestamp":1696013349000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/nyas.12424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1111\/nyas.12424"],"URL":"https:\/\/doi.org\/10.1111\/nyas.12424","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}